Symic Bio

Apr 25, 2019

Symic Bio Announces Closing of Investment led by CIP

Nov 09, 2018

Symic Bio Selected for "The Best of The Liver Meeting 2018" at AASLD

Apr 18, 2018

Symic Bio to Present at the 10th Annual ChinaBio Partnering Forum

Apr 16, 2018

Results from Symic Bio Liver Fibrosis Program Presented at the International Liver Congress 2018

Apr 02, 2018

Symic Bio Announces 12-Month Results from the SHIELD Trial of SB-030 in Peripheral Vascular Disease

Mar 05, 2018

Symic Bio Announces Results of Locally-Administered Therapeutic SB-030 in Preclinical Model of Vascular Intervention

Feb 07, 2018

Symic Bio Completes the MODIFY2 Phase 2 Trial of SB-061 for the Treatment of Knee Osteoarthritis

Jan 22, 2018

Symic Bio Appoints Hicham Alaoui, Ph.D., as Senior Vice President of Discovery Biology

Nov 03, 2017

Symic Bio Appoints Wayne Froland, Ph.D., as Executive Vice President of Technical Operations

Nov 01, 2017

Symic Bio Announces Results from the Phase 1/2 SHIELD Trial of SB-030 in Peripheral Vascular Disease

Oct 23, 2017

Symic Bio to Present at Upcoming Conferences in Tokyo and Berlin

Oct 02, 2017

Symic Bio to Present at Upcoming October Conferences

Sep 18, 2017

Symic Bio to Present at the Ladenburg Thalmann 2017 Annual Healthcare Conference

Aug 23, 2017

Symic Bio Enrolls First Patient in MODIFY2 Phase 2 Trial of SB-061 for the Treatment of Osteoarthritis

Jul 05, 2017

Symic Bio Appoints Matrix Biology Researcher and Professor Glenn Prestwich as Executive Vice President of Chemistry